Thrombosis prevention

Last updated
Thrombosis prevention
Blausen 0088 BloodClot.png
a blood clot blocking a blood vessel
Other namesThrombosis prophylaxis
ICD-10-PCS I80-I82
ICD-9-CM 437.6, 453, 671.5, 671.9

Thrombosis prevention or thromboprophylaxis is medical treatment to prevent the development of thrombosis (blood clots inside blood vessels) in those considered at risk for developing thrombosis. [1] Some people are at a higher risk for the formation of blood clots than others. Prevention measures or interventions are usually begun after surgery as people are at higher risk due to immobility.

Contents

People undergoing surgery with cancer are at an increased risk of blood clots. Blood thinners are used to prevent clots , these blood thinners have different effectiveness and safety profiles. Research [2] found 20 studies that included 9771 people with cancer. The evidence did not identify any difference between the effects of different blood thinners on death, developing a clot, or bleeding. Less bruising following surgery occurred with some while others may have reduced the risk of getting a blood clot but the reliability of evidence varied from low to moderate.

Data from five studies with 422 participants [3] suggested the effect of low molecular weight heparin (LMWH) on death compared with unfractionated heparin was uncertain.

There are medication-based interventions and non-medication-based interventions. [4] The risk of developing blood clots can be modified by life style modifications, the discontinuation of oral contraceptives, and weight loss. In those at high risk both interventions are often used. [1] The treatments to prevent the formation of blood clots is balanced against the risk of bleeding. [5]

One of the goals of blood clot prevention is to limit venous stasis as this is a significant risk factor for forming blood clots in the deep veins of the legs. [6] Venous stasis can occur during the long periods of not moving. Thrombosis prevention is also recommended during air travel. [7] Thrombosis prophylaxis is effective in preventing the formation of blood clots, their lodging in the veins, and their developing into thromboemboli that can travel through the circulatory system to cause blockage and subsequent tissue death in other organs. [1] Clarence Crafoord is credited with the first use of thrombosis prophylaxis in the 1930s.

Pathophysicology of blood clot prevention

Flow chart of clot prevention.jpg

The development of blood clots can be interrupted and prevented by the use of medication, changing risk factors and other interventions. Some risk factors can be modified. These would be losing weight, increasing exercise and the cessation of oral contraceptives. Moving during periods of travel is a modifiable behavior. Preventing blood clots includes the use of medications that interrupt the complex clotting cascade and changing the proteins that are needed for clotting. Antiplatelet drugs also have an effect in preventing the formation of clots.[ citation needed ]

If a blood clot has already formed in a blood vessel, treatment will differ significantly from clot prevention. Hemolytic medications are used. These are medications that will help dissolve the clot. Physical interventions then become contraindicated due to the risk of the clot migrating to distant locations like the heart, brain, and lungs. Once a clot has formed, a person will be prescribed bed rest and remain relatively immobile until it the clot is undetectable.[ citation needed ]

Medical treatments

Thrombosis prophylaxis is not only used for the prevention of deep vein thrombosis, but can be initiated for the prevention of the formation of blood clots in other organs and circumstances unrelated to deep vein thrombosis:

Epidemiology of developing blood clots

The risk of developing deep vein thrombosis, or pulmonary embolism is different than the total risk of the formation of blood clots. This is due to the observation that not all blood clots form in the lower legs. Most hospitalized medical patients have at least 1 risk factor for thrombosis that progresses to thromboembolism and this risk persists weeks after discharge. Those who remain undiagnosed and not treated prophylactically have a 26% chance of suffering a fatal embolism. Another 26% develop another embolism. Between 5% and 10% of all in hospital deaths are due to pulmonary embolism (as a consequence of thrombosis). Estimates of the incidence of pulmonary embolism in the US is 0.1% persons/year. Hospital admissions in the US for pulmonary embolism are 200,000 to 300,000 yearly. [10] [10] Thrombosis that develops into DVT will affect 900,000 people and kill up to 100,000 in the US. On average 28,726 hospitalized adults aged 18 and older with a VTE blood clot diagnosis die each year. [11] Risk of thrombosis is related to hospitalization. In 2005 the UK the Parliamentary Health Select Committee determined the annual rate of death due to thrombosis was 25,000 with at least 50% being hospital-acquired. [12]

The type of surgery performed prior to the formation of blood clots influences the risk. Without prophylactic interventions, the calculated incidence of clot formation in the lower leg veins after surgery is:

As the population of the US ages, the development of blood clots is becoming more common. [14]

General risks and indications for blood clot prevention

Some risk factors for developing blood clots are considered higher that others. One scoring system analyzes the probability for clot formation by assigning a point value system to significant risk factors. [15] The benefit of treating those who are at low risk of developing blood clots may not outweigh the higher risks of significant bleeding. [16]

Risk factors for developing blood clots that are assessed prior to treatments
Risk factorNotesReferences
Previous episodes of thrombosis also a risk factor for embolism formation [17] [18] [19]
Family History of Deep Vein Thrombosis [20] [14]
Gender, and race not firmly established
increased prevalence in women during childbearing years
[14]
Smoking modifiable, difficult [19] [21]
Diabetes [18]
Arteriosclerosis [18]
Renal disease ”hypercoagulable state” [18] [18]
Vasoconstriction [22]
Myocardial infarction and other types of heart diseaseHeart attack, Unstable angina Dysrhythmias Heart failure [23] [20] [22] [18]
Slow or turbulent blood flowmodifiable with exercise [22] [23] [24]
Stroke heparins contraindicated [24] [18] [24]
Sedentary life stylemodifiable with exercise [22] [19] [14]
Plaster casttransient [18]
Dehydration modifiable
also related to athletic activities and sports
[22] [20]
Acute respiratory failure [18]
Dysrhythmias [22] [23]
Shock [22]
Obesity modifiable [15] [25] [1] [22] [18] [23] [19]
Pregnancy and the post-partum period“hypercoagulable state” [18] [15] [1] [22] [20] [14]
Varicose veins [18]
Surgery length of the surgical procedure
type of operation
hip or knee surgery [14]
related to subsequent state of hypercoagulability [13]
[15] [1] [25] [19] [20] [21]
Lung disease [20]
Trauma related to immobility [15] [1] [18] [23] [14]
Estrogen-based oral contraceptive discontinuation reduces risk
related to progestogen and ethinylestradiol [26]
[15] [1] [22] [20] [26] [14] [21]
Hormone replacement therapy discontinuation reduces risk [15]
Ovarian hyper-stimulation therapy to treat infertility [15]
Compression of a vein or artery by abnormality, tumor, hematoma [15]
Pacing wires [1]
Local vein damage, incompetent valves [1] [22] [22]
Central venous catheters [1] [23]
Dialysis catheters [1] [23]
Repetitive motion injury [1]
Immobilityassociated with air travel, long travel times and
post-surgical – modifiable risk
[1] [18] [23] [19] [14] [21] [13]
Spinal cord injury [1]
Age [1] [15] [22] [18]
Cancers

[1] [20] [14]

Sepsis [1]
Polycythemia heparins contraindicated [24] [1]
genetic deficiencies or autoimmune disorders, Protein C and/or S deficiencycongenital; associated with warfarin necrosis, heparins contraindicated [24] [1] [27] [21]
Antiphospholipid antibody syndrome altered coagulation; heparins contraindicated [24] [1]
Factor V Leiden defect altered coagulation [1]
Prothrombin G20210A defectaltered coagulation; heparins contraindicated [24] [1]
Hyperhomocysteinimia altered coagulation; heparins contraindicated [24] [1]
Elevated factors II, VIII, IX, XI altered coagulation; heparins contraindicated [24] [1] [14]
Antithrobin III deficiency altered coagulation; heparins contraindicated [24] [1] [14]
Falls and hip fracture related to immobility [1] [19]
Selective estrogen-receptor modulators [15]
Erythropoiesis-stimulating agents [15]
Acute medical illness [15] [14]
Inflammatory bowel disease [15]
Nephrotic syndrome [15]
Myeloproliferative disorders [15]
Paroxysmal nocturnal hemoglobinnuria [15]
Thrombophilias heparins contraindicated [24] [15] [14]
Post-menopausal hormone replacement therapydiscontinuation reduces risk [15]
Right heart failure [22]
Venous inflammation/phlebitis when a thrombus forms, it is thrombophlebitis [22]
Sickle cell disease
Artificial heart valves [24]
Probability and risk estimation for developing blood clots
Major risk (=1 point)Minor risk (=2 points)
Cancer Family history of
deep vein thrombosis
ImmobilityHospitalization within
the past 6 months
Calf swelling superficial vein dilation
Recent major surgeryredness of area
Edema or swelling of only legRecent trauma
to leg
Tenderness in
the calf and/or thigh
Scoring of the risks associated with formation of blood clots
Probability determination and scoring
High probability scoring (12–7 points
3 major points OR
2 major points AND >2 minor points
Low probability scoring (3–5 points)
0 major points AND > 2 minor points
1 major point AND >2 minor points
0 major points and >3 minor point
1 major point and more than one minor point
Moderate probability scoring (varies)
all other risk combinations

Risk for subsequent blood clots

Developing blood clots is more probable after the first episode. Risk assessment and intervention for those with one or more episodes of deep vein thrombosis or blood clots in the veins utilizes the Well's test. It has been inconsistently modified by a number of publishers with the results listed below: [28]

Well's and modified Well's risk scoring

Well's and modified Well's scoring
Findingpointsreferences
D-dimer abonormal one month after stopping anticoagulants2 [28]
Age > or = to 501 [28]
male1 [28]
use of hormone at DVT onset1 [28]

Adapted for the emergency department

modified Well's scoring
Findingpointsreferences
Malignancy1 [29]
Age > or = to 501 [29]
cast on lower leg/Paralysis/paresis/1 [29]
Recent surgery or immobility1 [29]
tenderness over deep vein1 [29]
entire leg swollen1 [29]
difference of 3 cm between legs1 [29]
pitting edema of affected leg1 [29]
Collateral superficial veins1 [29]
another diagnosis more probable than DVT-2 [29]

Scoring:

General interventions

The Centers for Disease Control and Prevention have issued general guidelines describing the interventions that can be taken to reduce the risk of the formation of blood clots:

The Centers for Disease Control and Prevention recommend the following:
  • Move around as soon as possible after having been confined to bed, such as after surgery, illness, or injury.
  • If you’re at risk for DVT, talk to your doctor about:
  • Graduated compression stockings (sometimes called "medical compression stockings")
  • Medication (anticoagulants) to prevent DVT.
  • When sitting for long periods of time, such as when traveling for more than four hours:
  • Get up and walk around every 2 to 3 hours.
  • Exercise your legs while you’re sitting by:
  • Raising and lowering your heels while keeping your toes on the floor
  • Raising and lowering your toes while keeping your heels on the floor
  • Tightening and releasing your leg muscles
  • Wear loose-fitting clothes.
  • You can reduce your risk by maintaining a healthy weight, avoiding a sedentary lifestyle, and following your doctor's recommendations based on your individual risk factors. [7]
Venous valve 00013.gif

Interventions during travel

Seat-edge pressure from the seat on an airplane on the popliteal area may contribute to vessel wall damage as well as venous stasis. Coagulation activation may result from an interaction between cabin conditions (such as hypobaric hypoxia) and individual risk factors for the formation of blood clots. Studies of the pathophysiologic mechanisms for the increased risk of Venous thrombosis embolism or VTE after long-distance travel have not produced consistent results, but venous stasis appears to play a major role; other factors specific to air travel may increase coagulation activation, particularly in passengers with individual risk factors for VTE. [30]

Interventions for those hospitalized

Compression devices

The use of fitted intermittent pneumatic compression devices before, during and after procedures is another way to It consists of an air pump and inflatable auxiliary compartments that sequentially inflates and deflated to provide an external 'pump' that returns venous blood toward the heart. [31] The use of intermittent pneumatic compression is common. [31] [19] [5] These devices are also placed on a surgical patient in the operating room (the intra-surgical period) and remain on the person while recovering from the surgery. [32]

The application of antiembolism stockings (TED stockings) can be used to prevent thrombosis. The correct use and properly fitted graded compression stockings can reduce the rate of thrombosis by 50%. [15] [19] :745–46 Contraindications for the use of antiembolism stockings include the presence of advanced peripheral and obstructive arterial disease, septic phlebitis, heart failure, open wounds, dermatitis and peripheral neuropathy. [33] Differences between the use of thigh-high compression stockings and shorter types to prevent blood clots exist, but remain inconsistent. [5]

Assessment

There has been some success in preventing blood clots by an early risk assessment upon admission to the hospital, which is a strategy recognized by the Centers for Disease Control and Prevention. Hospitals that have participated in this effort to reduce the incidence of thrombosis found that rates of DVT decreased in some instances. [34] Some of the hospitals developed a mandatory assessment quantifying the risk for developing blood clots and a plan of care developed from the assessment. The person's risk for developing blood clots is entered into their record, ‘following’ them through their treatment regime. If the hospital stay exceeded three days, the person was reassessed for risk. Clinicians were then able to apply protocols for prevention based upon best clinical practices. [35] [36]

Interventions to treat immobility

The poplitial vein can be one site of venous stasis in the lower leg. Obstruction of this vein during travel contributes to statis. Poplitial vein.jpg
The poplitial vein can be one site of venous stasis in the lower leg. Obstruction of this vein during travel contributes to statis.

Immobility is a significant risk factor in the development of thrombosis. [37] [38] [22] [25] Immediate post-surgical interventions, such as out of bed orders (OOB), are typically ordered by the physician to prevent thrombosis. These orders, typically delegated to a nurse, but may include the participation of a physical therapist and others trained to perform the intervention, are to perform range of motion (ROM) activities that include: muscle contractions of the lower legs for those who are very weak, moving the feet, wiggling the toes, bending the knees, raise and lower the legs. In addition, changes in positioning prevents immobility and shifts areas of venous stasis. If the person is too weak to perform these preventative activities, hospital personnel will perform these movements independently. Exercise of the lower extremities is a post-operative method of prophylaxis. Nursing personnel will often perform range of motion exercises and encourage frequent moving of the legs, feet, and ankles. Frequent positioning changes and adequate fluid intake. After a surgical procedure, ambulation as soon as possible is prophylactic in preventing the formation of blood clots. [38] [22] [25]

Early ambulation also prevents venous stasis and physicians order OOB activities on the same day of surgery. This is accomplished in increments. The progression of increasing mobility proceeds by: raising the head of the bed, sitting up in bed, moving to the edge of the bed, dangling the legs off the bed and then ambulating to a close chair. [19] [25]

Patient education and compliance reduces the risk of developing blood clots. These exercises and use of equipment and follow up by clinicians reduces the risk of developing blood clots. [25]

Note that if a blood clot has already formed in the deep veins of the leg, bedrest is usually prescribed and the treatment to prevent bloods with physical intervention is contraindicated.

Medication

Anticoagulants and antiplatelets

Thromboprophylaxis, such as anticoagulants or pre-operative low-molecular weight heparin, is effective for hospitalized patients at risk for VTE. [39] Additional risk factors such as obesity, disease, malignancies, long surgeries, and immobility may influence the prescribed dosage. Anticoagulant medications prevent the formation of blood clots in people who are at high risk for their development. Treating blood clots that have already formed is managed by the use of anti-hemolytic ("clot busters"). Despite its effectiveness, the use of thromboprophylaxis remains under-utilized, though alerts (computer or human) in hospitals are associated with increased prescription and reductions in symptomatic VTE. [39] The list below describes some of the more common medications used to prevent blood clots. [24] Note that generally that since blood clotting is inhibited, a side effect typically is bleeding, though it can be reversed by administering a medication that stops the bleeding or by discontinuation of the medication itself. Anti-coagulant administration is often given before the start of the operation. There are concerns with the potential of increased risk of bleeding and so many surgeons start giving anti-coagulants the first 6 hours after surgery. [25] Medications that inhibit blood clot formation include:

Medications used to prevent blood clots
Name of medicationTherapeutic/pharmologic classActionRouteOther usesNotesSide effectsReferences
aspirin antiplateletrisks for GI tract bleeding and hemorrhagic stroke [40] [41] [32] [42] [43]
dipyridamole platelet aggregation inhibitor oral or IV Abdominal or stomach cramps, diarrhea, dizziness or lightheadedness [44] [45] [46] [41]
clopidogrel antiplatelet [45] [41]
ticlid
enoxaparin anticoagulantactivation of antiprothrombin, prevents fibrin formationslow IVplatelet count is monitored [45] [41]
dalteparin anticoagulantactivation of antiprothrombin, prevents fibrin formationIV [41]
fondaparinux anticoagulantinhibits thrombin productioninjectionaspirin not recommended with this medication [41] [24]
dabigatran inhibits prothrombin [41]
bivalirudin inhibits prothrombinoften given with aspirin [41]
argatroban anticoagulantinhibits prothrombinIValternative to heparin in those developing heparin-induced thrombocytopenia [41] [24]
desirudin anticoagulantinhibits prothombininjectionused with hip replacement [41] [24]
eptifiatide antiplatelet [41]
tirofiban antiplatelet [41]
ticlopidine antiplatelet [41]
pentocifylline antiplatelet [41]
diyridamole anitplatelet [41]
cilostazol antiplatelet [41]
rivaroxaban inhibits factor Xause with antiplatelets cautionedGI bleeding [41]
warfarin anticoagulantThrombin inhibitor;IV [24]
lipirudin anticoagulantinhits prothrombinIVtreatment may extend to 10 days [24]

Heparins

Heparin Prophylaxis
nameactionstructurereferences
Low-molecular weight heparin
(example: Reviparin)
[47] [48] [49] [50] [51]

The discontinuation of contraceptives also prevents blood clots. [15]

Herbal interactions

The therapeutic effects of warfarin may be decreased by valerian. Anticoagulants can be affected by chamomile. Dong quai, garlic, ginger, Ginkgo biloba, bilberry and feverfew can increase bleeding time. These same herbal supplements taken with warfarin increased prothrombin time. [24]

Dietary interactions

By containing significant content of vitamin K, some foods act as antagonists to antiplatelet and anticoagulant medications; these include green leafy vegetables, like spinach, legumes, and broccoli. [24]

Contraindications

Preventing blood clots with medication is not considered safe in the following circumstances:

Adding heparin to the use of compression stockings may prevent thrombosis. [52]

Research

An international registry and risk assessment calculator is being used to centralize data on post-surgical venous thrombosis and its prevention. [53] Hospitals are implementing a multi-disciplinary approach to prevent of blood clots. This includes adequate assessment of the risks, follow up on missed doses of medication and instituting a 'patient-centered' approach endorsed by the Joint Commission. [34] Recommendations regarding the prevention of blood clots vary widely between clinicians and treatment facilities. Research continues to clarify these discrepancies. [5] The metabolic state of hypercoagulability (the tendency to form blood clots) tests are being developed. These include the evaluation of the thrombin–antithrombin complexes (TAT), low levels of the anticoagulants ATIII and protein C, but these tests are not yet widely available. [13]

Related Research Articles

Anticoagulant class of drugs

Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as sample tubes, blood transfusion bags, heart-lung machines, and dialysis equipment. One of the first anticoagulants, warfarin, was initially approved as a rodenticide.

Thrombosis Vascular disease caused by the formation of a blood clot inside a blood vessel

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel is injured, the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot, or a piece of the clot, that breaks free and begins to travel around the body is known as an embolus.

Venous thrombosis Blood clot (thrombus) that forms within a vein

A venous thrombosis is a thrombosis in a vein, caused by a thrombus. A common type of venous thrombosis is a deep vein thrombosis (DVT), which is a blood clot usually found in the deep veins of the leg. It is increasingly found in the deep veins of the arm, accounting for more than 10% of all deep vein thromboses. If the thrombus breaks off (embolizes) and flows towards the lungs, it can become a pulmonary embolism (PE), a blood clot in the lungs. This combination is called venous thromboembolism. Various other forms of venous thrombosis also exist; some of these can also lead to pulmonary embolism.

Factor V Leiden is a variant of human factor V, which causes an increase in blood clotting (hypercoagulability). Due to this mutation, Protein C, an anticoagulant protein which normally inhibits the pro-clotting activity of factor V, is not able to bind normally to Factor V, leading to a hypercoagulable state, i.e., an increased tendency for the patient to form abnormal and potentially harmful blood clots. Factor V Leiden is the most common hereditary hypercoagulability disorder amongst ethnic Europeans. It is named after the Dutch city Leiden, where it was first identified in 1994 by Prof R. Bertina under the direction of Prof P. Reitsma. Despite the increased risk of VTE, people with one copy of this gene have not been found to have shorter lives than the general population.

Deep vein thrombosis Formation of a blood clot (thrombus) in a deep vein

Deep vein thrombosis (DVT) is the formation of a blood clot in a deep vein, most commonly in the legs or pelvis. Symptoms can include pain, swelling, redness, and enlarged veins in the affected area, but some DVTs have no symptoms. The most life-threatening concern with DVT is the potential for a clot to detach, travel through the right side of the heart, and become stuck in arteries that supply blood to the lungs. This is called pulmonary embolism (PE). Both DVT and PE are considered as part of the same overall disease process, which is called venous thromboembolism (VTE). VTE can occur as an isolated DVT or as PE with or without DVT. The most frequent long-term complication is post-thrombotic syndrome, which can cause pain, swelling, a sensation of heaviness, itching, and in severe cases, ulcers. Also, recurrent VTE occurs in about 30% of those in the ten years following an initial VTE.

Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. They are used in the prevention of blood clots and treatment of venous thromboembolism and in the treatment of myocardial infarction.

Renal vein thrombosis

Renal vein thrombosis (RVT) is the formation of a clot in the vein that drains blood from the kidneys, ultimately leading to a reduction in the drainage of one or both kidneys and the possible migration of the clot to other parts of the body. First described by German pathologist Friedrich Daniel von Recklinghausen in 1861, RVT most commonly affects two subpopulations: newly born infants with blood clotting abnormalities or dehydration and adults with nephrotic syndrome.

Rivaroxaban Anticoagulant drug

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

Dalteparin sodium Pharmaceutical drug

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.

Compression stockings Compression garment

Compression stockings are a specialized hosiery designed to help prevent the occurrence of, and guard against further progression of, venous disorders such as edema, phlebitis and thrombosis. Compression stockings are elastic compression garments worn around the leg, compressing the limb. This reduces the diameter of distended veins and increases venous blood flow velocity and valve effectiveness. Compression therapy helps decrease venous pressure, prevents venous stasis and impairments of venous walls, and relieves heavy and aching legs.

Post-thrombotic syndrome venous insufficiency that is characterized by aching pain, heaviness, swelling, cramps, itching, or tingling in the affected limb and is a chronic complication of deep venous thrombosis

Post-thrombotic syndrome (PTS), also called postphlebitic syndrome and venous stress disorder is a medical condition that may occur as a long-term complication of deep vein thrombosis (DVT).

Bemiparin sodium pharmaceutical drug

Bemiparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).

Venous stasis condition of slow blood flow in the veins, usually of the legs

Venostasis, or venous stasis, is a condition of slow blood flow in the veins, usually of the legs.

Intermittent pneumatic compression

Intermittent pneumatic compression is a therapeutic technique used in medical devices that include an air pump and inflatable auxiliary sleeves, gloves or boots in a system designed to improve venous circulation in the limbs of patients who suffer edema or the risk of deep vein thrombosis (DVT) or pulmonary embolism (PE).

Edoxaban anticoagulant drug

Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth.

Betrixaban chemical compound

Betrixaban is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications due to restricted mobility and other risk factors. Compared to other DOACs betrixaban has relatively low renal excretion and is not metabolized by CYP3A4.

Apixaban Anticoagulant drug, a direct inhibitor of factor X, also used in the prevention of venous thromboembolism

Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. It is taken by mouth.

Prothrombin G20210A is a genetic condition that increases the risk of blood clots including deep vein thrombosis and pulmonary embolism. One copy of the mutation increases the risk of a blood clot from 1 in 1,000 per year to 2.5 in 1,000. Two copies increases the risk to up to 20 in 1,000 per year. Most people never develop a blood clot in their lifetimes.

Superficial vein thrombosis

Superficial vein thrombosis (SVT) is a type blood clot in a vein, which forms in a superficial vein near the surface of the body. Usually there is thrombophlebitis, which is an inflammatory reaction around a thrombosed vein, presenting as a painful induration with redness. SVT itself has limited significance when compared to a deep vein thrombosis (DVT), which occurs deeper in the body at the deep venous system level. However, SVT can lead to serious complications, and is therefore no longer regarded as a benign condition. If the blood clot is too near the saphenofemoral junction there is a higher risk of pulmonary embolism, a potentially life-threatening complication.

Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a safer anticoagulant.

References

Blue question mark icon.svg Using Wikipedia for Research

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Brunner L (2010). Brunner & Suddarth's textbook of medical-surgical nursing. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 876. ISBN   978-0781785907.
  2. Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosuico VE, et al. (July 2018). "Anticoagulation for perioperative thromboprophylaxis in people with cancer". The Cochrane Database of Systematic Reviews. 7: CD009447. doi:10.1002/14651858.cd009447.pub3. PMC   6389341 . PMID   29993117.
  3. Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, et al. (January 2018). "Anticoagulation for the initial treatment of venous thromboembolism in people with cancer". The Cochrane Database of Systematic Reviews. 1: CD006649. doi:10.1002/14651858.cd006649.pub7. PMC   6389339 . PMID   29363105.
  4. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C (December 2005). "Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis". Health Technology Assessment. 9 (49): iii–iv, ix–x, 1–78. doi: 10.3310/hta9490 . PMID   16336844.
  5. 1 2 3 4 Grotta J (2016). Stroke : pathophysiology, diagnosis, and management. Philadelphia: Elsevier. pp. 953–62. ISBN   978-0323295444.
  6. Martinelli I, Bucciarelli P, Mannucci PM (February 2010). "Thrombotic risk factors: basic pathophysiology". Critical Care Medicine. 38 (2 Suppl): S3-9. doi:10.1097/CCM.0b013e3181c9cbd9. PMID   20083911. S2CID   34486553.
  7. 1 2 "Venous Thromboembolism (Blood Clots) Facts". Division of Blood Disorders National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. 24 February 2016. Retrieved 2016-07-19.PD-icon.svgThis article incorporates text from this source, which is in the public domain.
  8. "ICD-10 Version:2016". International Statistical Classification of Diseases and Related Health Problems 10th Revision. Retrieved 2016-12-18.
  9. Leveno K (2013). Williams manual of pregnancy complications. New York: McGraw-Hill Medical. ISBN   978-0071765626.
  10. 1 2 Kafeza M, Shalhoub J, Salooja N, Bingham L, Spagou K, Davies AH (September 2017). "A systematic review of clinical prediction scores for deep vein thrombosis". Phlebology. 32 (8): 516–531. doi:10.1177/0268355516678729. hdl: 10044/1/41102 . PMID   27885107. S2CID   13759574.
  11. "Venous Thromboembolism (VTE)" (PDF). National Center on Birth Defects and Developmental Disabilities. Archived from the original (PDF) on 23 October 2018.PD-icon.svgThis article incorporates text from this source, which is in the public domain.
  12. Hunt BJ (March 2008). "Awareness and politics of venous thromboembolism in the United kingdom". Arteriosclerosis, Thrombosis, and Vascular Biology. 28 (3): 398–9. doi: 10.1161/ATVBAHA.108.162586 . PMID   18296598.
  13. 1 2 3 4 Newman M (2008). Perioperative medicine : managing for outcome . Philadelphia: Saunders Elsevier. pp.  29–34. ISBN   978-1437721263.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Henke PK, Meissner MH, Wakefield TW. "Chapter 2: Risk Factors for Venous Thrombosis" (PDF). American Venous Forum. Archived from the original (PDF) on 27 September 2016. Retrieved 2016-12-24.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Hoffman B (2012). Williams gynecology. New York: McGraw-Hill Medical. p. 960–8. ISBN   978-0071716727.CS1 maint: ref=harv (link)
  16. Cameron AC, McCallum L, Gardiner T, Darroch C, Walters MR, Oldroyd KG (November 2015). "Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome - a prospective audit". British Journal of Clinical Pharmacology. 80 (5): 1176–84. doi:10.1111/bcp.12714. PMC   4631190 . PMID   26147691.
  17. "Patients with Venous Thromboembolism ) Registry". RIETE. Retrieved 2016-12-20.
  18. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Moliterno D (2013). Therapeutic advances in thrombosis. Chichester, West Sussex: Wiley-Blackwell. pp. 306–327. ISBN   978-1405196253.
  19. 1 2 3 4 5 6 7 8 9 10 Rosdahl C (2012). Textbook of basic nursing . Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p.  789. ISBN   978-1605477725.
  20. 1 2 3 4 5 6 7 8 "DVT: Myths vs. Facts | American Society of Hematology" . Retrieved 2016-12-22.
  21. 1 2 3 4 5 Drake R (2012). Gray's basic anatomy, with Student Consult. Philadelphia: Elsevier/Churchill Livingstone. pp. 133–205. ISBN   978-1455710782.
  22. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Copstead L (2013). Pathophysiology. St. Louis, Mo: Elsevier. p. 320–9. ISBN   978-1455726509.
  23. 1 2 3 4 5 6 7 8 Lilley, p. 423.
  24. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Kee J (2012). Pharmacology : a nursing process approach . St. Louis, MO: Elsevier Saunders. p.  670–7. ISBN   978-1437717112.
  25. 1 2 3 4 5 6 7 Abele H (2014). Atlas of gynecologic surgery. Stuttgart: Thieme. ISBN   978-3136507049; Access provided by the University of Pittsburgh
  26. 1 2 de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (March 2014). "Combined oral contraceptives: venous thrombosis". The Cochrane Database of Systematic Reviews (3): CD010813. doi:10.1002/14651858.CD010813.pub2. PMID   24590565.
  27. Swystun LL, Liaw PC (August 2016). "The role of leukocytes in thrombosis". Blood. 128 (6): 753–62. doi: 10.1182/blood-2016-05-718114 . PMID   27354721.
  28. 1 2 3 4 5 Modi S, Deisler R, Gozel K, Reicks P, Irwin E, Brunsvold M, et al. (2016). "Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients". World Journal of Emergency Surgery. 11 (1): 24. doi:10.1186/s13017-016-0078-1. PMC   4898382 . PMID   27279896.
  29. 1 2 3 4 5 6 7 8 9 10 11 Markovchick V (2016). Emergency medicine secrets. Philadelphia, PA: Elsevier. pp. 190–95. ISBN   978-0323355162.
  30. "Deep Vein Thrombosis & Pulmonary Embolism, Chapter 2, Travelers' Health". CDC. Retrieved 2016-12-25.PD-icon.svgThis article incorporates text from this source, which is in the public domain.
  31. 1 2 Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM (February 2012). "Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis 9th ed, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e227S–e277S. doi:10.1378/chest.11-2297. PMC   3278061 . PMID   22315263.
  32. 1 2 Stewart DW, Freshour JE (January 2013). "Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence". The Annals of Pharmacotherapy. 47 (1): 63–74. doi:10.1345/aph.1R331. PMID   23324504. S2CID   9366072.
  33. Stemmer R (February 2013). "Compression Bulletin 24" (PDF). Sigvaris. p. 2. Archived from the original (PDF) on 2015-06-20. Retrieved 21 December 2016.
  34. 1 2 Streiff MB, Lau BD, Hobson DB, Kraus PS, Shermock KM, Shaffer DL, et al. (December 2016). "The Johns Hopkins Venous Thromboembolism Collaborative: Multidisciplinary team approach to achieve perfect prophylaxis". Journal of Hospital Medicine. 11 Suppl 2: S8–S14. doi: 10.1002/jhm.2657 . PMID   27925423.
  35. "The 2015 Healthcare-Associated Venous Thromboembolism Prevention Challenge Champions". CDC. 7 December 2016. Retrieved 2016-12-28.PD-icon.svgThis article incorporates text from this source, which is in the public domain.
  36. Minami CA, Yang AD, Ju M, Culver E, Seifert K, Kreutzer L, et al. (December 2016). "Evaluation of an institutional project to improve venous thromboembolism prevention". Journal of Hospital Medicine. 11 Suppl 2: S29–S37. doi: 10.1002/jhm.2663 . PMID   27925424.
  37. "Frequently Asked questions". Thrombosis UK. 2015. Retrieved 2016-12-29.
  38. 1 2 Potter P (2013). Fundamentals of nursing. St. Louis, Mo: Mosby Elsevier. p. 1149. ISBN   978-0323079334.
  39. 1 2 Kahn, Susan R.; Morrison, David R.; Diendéré, Gisèle; Piché, Alexandre; Filion, Kristian B.; Klil-Drori, Adi J.; Douketis, James D.; Emed, Jessica; Roussin, André; Tagalakis, Vicky; Morris, Martin (24 April 2018). "Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism". The Cochrane Database of Systematic Reviews. 4: CD008201. doi:10.1002/14651858.CD008201.pub3. ISSN   1469-493X. PMC   6747554 . PMID   29687454.
  40. "Evidence Summary: Bleeding Risks With Aspirin Use: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication". US Preventive Services Task Force. April 2016. Retrieved 2016-12-29.
  41. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Henry N (2016). RN pharmacology for nursing : review module. Overland Park, KS: Assessment Technologies Institute. pp. 191–98. ISBN   978-1565335738.
  42. "Final Update Summary: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication". US Preventive Services Task Force. April 2016. Retrieved 2016-12-29.
  43. "Talk with Your Doctor about Taking Aspirin Every Day". US Preventive Services Task Force. April 2016. Retrieved 2016-12-29.
  44. " Dipyridamole " at Dorland's Medical Dictionary
  45. 1 2 3 "Recommended Use of Aspirin and Other Antiplatelet Medications Among Adults, National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005–2008". Centers for Disease Control and Prevention. 15 June 2012. Retrieved 2016-12-29.
  46. "Dipyridamole Monograph for Professionals" . Retrieved 2016-12-29.
  47. Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thrombosis Research. 81 (2 Suppl): S39-45. doi:10.1016/0049-3848(95)00228-6. PMID   8822126.
  48. Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Seminars in Thrombosis and Hemostasis. 25 Suppl 3: 79–82. PMID   10549720.
  49. Bruner, p. 875–6.
  50. Garcia DA, Baglin TP, Weitz JI, Samama MM (February 2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e24S–e43S. doi:10.1378/chest.11-2291. PMC   3278070 . PMID   22315264.
  51. Azhar RA, Bochner B, Catto J, Goh AC, Kelly J, Patel HD, et al. (July 2016). "Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs". European Urology. 70 (1): 176–187. doi:10.1016/j.eururo.2016.02.051. PMC   5514421 . PMID   26970912.
  52. Zareba P, Wu C, Agzarian J, Rodriguez D, Kearon C (August 2014). "Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery". The British Journal of Surgery. 101 (9): 1053–62. doi:10.1002/bjs.9527. PMID   24916118.
  53. "Computerized Registry of Patients with Veneous Thromboembolism — RIETE Registry". S & H Medical Science Service. Retrieved 2016-02-13.